Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 21 of 114, showing 5 Applications out of 570 total, starting on record 101, ending on 105

# Protocol No Study Title Investigator(s) & Site(s)

101.

ECCT/24/05/05   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Kariuki Simon Kariuki
2. Patricia Odero Ojwang
Site(s) in Kenya
1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county)
 
View

102.

ECCT/24/05/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county)
 
View

103.

ECCT/24/05/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county)
 
View

104.

ECCT/24/04/08   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Wilson Muraya
Site(s) in Kenya
1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county)
 
View

105.

ECCT/24/04/07   FORMATIVE-PEARLS TRIAL
    PEARLS FORMATIVE  (Preventing pre-eclampsia: Evaluating AspiRin Low-dose regimens following risk Screening)    
Principal Investigator(s)
1. Zahida Qureshi
2. Alfred Osoti
3. George Gwako
4. Rosa Chemwey
Site(s) in Kenya
1. Kakamega General County Teaching and Referral Hospital (Kakamega county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Kiambu Level 5 Hospital (Kiambu county)
4. Kisii Teaching and Referral Hospital (Kisii county)
5. Meru Teaching and Referral Hospital (Meru county)
 
View